News

Kodiak's Zenkuda and tabirafusp ted meet primary endpoints in Phase 3 DAYBREAK wet AMD trial

What's the deal? Kodiak Sciences reported on28 September ️⃣2️⃣0️⃣2️⃣6️⃣ that both of its investigational ophthalmology assets — Zenkuda(tarcocimab tedromer(and tabirafusp alfa tedromer — met the primary endpoint inthe Phase ️⃣3️⃣ DAYBREAK study inwet age-related macular degeneration(wAMD(,. The trial compared the candidates with Regeneron'sEylea(aflibercept(,ananti-VEGF therapy,andKodiak said the study showed non-inferiorityin best-corrected visual acuity gains versus aflibercept at year one,withno new safety signals.(,

Why it matters: DAYBREAK is the first Phase ️⃣3️⃣ readout for Kodiak's resurrected pipeline,andthe positive results — which sent the company's shares up sharply — support Kodiak'splan to submit an application to the US FDA inthe fourth quarter,covering five Phase ️⃣3️⃣ trials across wet AMD,diabetic retinopathy,andretinal vein occlusion. If approved,Zenkuda,a novel anti-VEGF designed foresxtendeddosing,would entera crowded but high-value market dominatedbyEylea andRoche'sVabysmo,andthe company iso also advancing tabirafusp ted,which combines anti-VEGF andanti-IL-6 activity,in diabetic macular oedema.

Read more: Kodiak Sciences · Fierce Biotech

More top stories